Davion Healthcare Buys Humaskan for $60M

Davion Healthcare is significantly bolstering its digital health capabilities with a strategic acquisition of Humaskan, a medical technology firm specializing in proprietary healthcare products and intellectual property. The transaction, valued at $60 million, marks a pivotal step in Davion's ambition to construct a comprehensive healthcare ecosystem.

The deal structure involves $10 million in cash alongside $50 million in ordinary shares of Davion, issued at a reference price of $13.00 per share. These shares will be subject to a nine-month lock-up period, followed by provisions for orderly market disposal, ensuring a measured integration into the market.

This move follows Davion's recent acquisition of Solar Medical and Chemical Limited, which is designed to establish a crucial commercial and distribution hub within the United Kingdom. The combined strategy underscores Davion's commitment to building a scalable platform through a blend of internal product development, robust commercial infrastructure, strategic financing, and targeted acquisitions.

Further demonstrating its strategic financial planning, Davion is establishing Davion Healthcare Finance Ltd, a wholly-owned United Kingdom subsidiary. This entity is slated to support the company's aggressive acquisition and expansion initiatives across both the United States and Europe. A key objective for this subsidiary is the potential establishment of a corporate bond program, aiming to raise up to £100 million, subject to market conditions and regulatory approvals.

The proposed bond program, anticipated to launch around August 2026, is envisioned with three series (up to £30 million, £30 million, and £40 million respectively). These bonds are expected to offer an indicative fixed coupon of 10.5% annually with a five-year maturity. They will be exclusively offered to professional, sophisticated, and institutional investors, with potential admission to trading on the Vienna Stock Exchange MTF platform.

Proceeds from this financing initiative are earmarked to fuel Davion's acquisition pipeline, providing essential capital flexibility for disciplined deployment. Jack Kaye, CEO of Davion Healthcare, emphasized that the Humaskan acquisition and the finance subsidiary's formation are integral to creating a broader, more scalable healthcare platform. He stated, "We believe combining proprietary technologies, commercial capability, targeted acquisitions and access to long-term institutional capital has the potential to create a flexible foundation for future growth."

The healthcare technology sector continues to see significant M&A activity as companies seek to consolidate market share and enhance their product offerings. The digital health market, in particular, is projected for substantial growth, driven by increasing demand for remote monitoring and early disease detection solutions. Davion's strategic moves position it to capitalize on these trends, aiming to create a robust financing and operational framework for sustained value creation.